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Abstract
Background: There is evidence that renal transplant recipients have accelerated atherosclerosis
manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis
is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative stress and
inflammation associated with immunosuppressive therapy. The dietary supplement astaxanthin has
shown promise as an antioxidant and anti-inflammatory therapeutic agent in cardiovascular disease.
The aim of this trial is to investigate the effects of astaxanthin supplementation on arterial stiffness,
oxidative stress and inflammation in renal transplant patients.
Method and Design: This is a randomised, placebo controlled clinical trial. A total of 66 renal
transplant recipients will be enrolled and allocated to receive either 12 mg/day of astaxanthin or an
identical placebo for one-year. Patients will be stratified into four groups according to the type of
immunosuppressant therapy they receive: 1) cyclosporine, 2) sirolimus, 3) tacrolimus or 4)
prednisolone+/-azathioprine, mycophenolate mofetil or mycophenolate sodium. Primary outcome
measures will be changes in 1) arterial stiffness measured by aortic pulse wave velocity (PWV), 2)
oxidative stress assessed by plasma isoprostanes and 3) inflammation by plasma pentraxin 3.
Secondary outcomes will include changes in vascular function assessed using the brachial artery
reactivity (BAR) technique, carotid artery intimal medial thickness (CIMT), augmentation index
(AIx), left ventricular afterload and additional measures of oxidative stress and inflammation.
Patients will undergo these measures at baseline, six and 12 months.
Discussion: The results of this study will help determine the efficacy of astaxanthin on vascular
structure, oxidative stress and inflammation in renal transplant patients. This may lead to a larger
intervention trial assessing cardiovascular morbidity and mortality.
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Background
Vascular disease is the leading cause of morbidity and
mortality in renal transplant recipients [1]. Measures of
arterial stiffness such as aortic pulse wave velocity (PWV)
predict morbidity and mortality in patients with kidney
disease [2]. In addition, numerous studies have reported
elevated levels of oxidative stress and inflammation in
this population [3-7] and this has been associated with
arterial stiffness [8]. Our research group has shown that
cyclosporine, a commonly used immunosuppressant
taken by renal transplant recipients, increases markers of
oxidative stress [9,10] and decreases vascular function
[11]. In addition, antioxidant supplementation reduced
oxidative stress and protected against the cyclosporine-
induced vascular dysfunction [11].
Nutritional antioxidants have the ability to decrease lipid
and protein oxidation, potentially protecting against
atherosclerosis and arterial stiffening [12]. Although data
from epidemiological [13-16], animal [17] and in vitro
[18] studies has supported the notion that an increased
antioxidant intake will decrease the risk of atherosclerosis
and vascular disease, large randomised controlled trials
have not supported this postulate [19,20]. Thus, more
research is needed, especially in high-risk groups such as
renal transplant recipients. Importantly, new antioxidants
with different biological actions need to be investigated.
Astaxanthin is a carotenoid, belonging to the same family
as beta-carotene. Compared with other carotenoids it con-
tains two additional oxygenated groups on each ring
structure, resulting in enhanced antioxidant properties
[21]. The compound occurs naturally in a wide variety of
living organisms including microalgae, fungi, complex
plants and crustaceans. It is reddish-coloured and gives
salmon, shrimp and lobster their distinctive appearance.
It quenches reactive oxygen and nitrogen species, single
and two electron oxidants, and is a chain breaker of free
radicals. The most common source of astaxanthin used in
dietary supplements is from Haematococcus alga. The
United States Food and Drug Administration approved
astaxanthin as a nutaceutical [21]. Recently astaxanthin,
which has up to 500 times the potency of vitamin E, has
been suggested to play a valuable role in antioxidant pro-
tection of cells and in protection against cardiovascular
disease [22].
Preclinical studies have demonstrated that astaxanthin
supplementation has anti-inflammatory properties
[23,24] and potential efficacy in ischemia-reperfusion
[25,26], reduction of lipid peroxidation [27,28], and
rethrombosis after thrombolysis [29]. Only a few studies
have investigated the potential benefits of astaxanthin in
human health (Table 1). It has been shown that astaxan-
thin reduces reflux symptoms [30], improves age-related
macular degerenaration [31] and sperm parameters [32].
Another study reported astaxanthin supplementation had
no effect on muscle injury following intense exercise [33].
In addition, studies conducted in humans and animals
have found significant reductions in oxidative stress, dys-
lipidemia and inflammatory markers after oral supple-
mentation with astaxanthin [27,34,35].
The studies in humans have used astaxanthin in a range of
different doses, for various durations with no reported
side effects (Table 1). A study conducted in 35 healthy
adults specifically investigated the safety of astaxanthin
supplementation [36]. The study was a randomised, dou-
Table 1: Clinical studies investigating the effects astaxanthin
Study Dosage Duration of supplementation Findings
Iwamoto et al. 2000 [27] Different doses: 1.8, 3.6, 14.4, 21.6 
mg/day
2 weeks Inhibition of LDL oxidation
Mercke Odeberg et al. 2003 [49] 40 mg Single dose Enhanced bioavailability with lipid based 
formulation
Spiller et al. 2003 [36] 6 mg/day (3 × 2 mg tablets/day) 8 weeks Safety demonstrated in humans over 8 
weeks
Comhaire et al. 2005 [32] 16 mg/day 12 weeks Improved sperm parameters
Bloomer et al. 2005 [33] 4 mg/day 12 weeks No effect on muscle injury
Andersen et al. 2007 [35] 40 mg/day 8 weeks No effect on H pylori density or gastric 
inflammation
Karppi et al. 2007 [34] 8 mg/day 12 weeks Intestinal absorption adequate with 
Capsules. Decreases oxidation of fatty 
acids
Kupcinskas et al. 2008 [30] 16 mg or 40 mg/day 4 weeks Greater reduction in reflux symptoms in 
40 mg treated patients and more 
pronounced if H pylori positive
Parisi et al. 2008 [31] 4 mg/day 12 months Improved central retinal dysfunction in 
age related macular degeneration when 
administered with other antioxidantsBMC Nephrology 2008, 9:17 http://www.biomedcentral.com/1471-2369/9/17
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ble blind, placebo controlled trial in which participants
were required to consume 6 mg of astaxanthin per day for
eight weeks. Measures of blood pressure and blood chem-
istry conducted at four and eight weeks, revealed no sig-
nificant differences between the treatment and placebo
group and the authors concluded that 6 mg of astaxanthin
per day from a Haematococcus pluvialis algal extract can
be safely consumed by healthy adults.
At this stage, little is known regarding the effectiveness of
antioxidant supplementation on vascular disease in renal
transplant patients. A recent study from our research team
showed that antioxidant supplementation had an effect
on blood cyclosporine concentrations and renal function
[37]. Therefore, additional studies that improve our
understanding of antioxidant efficacy may lead to impor-
tant clinical benefits in the prevention of atherosclerosis
and vascular disease in these patients. The purpose of this
study is to assess the effect of antioxidant supplementa-
tion with astaxanthin on arterial stiffness, oxidative stress
and inflammation in renal transplant patients.
Methods and design
Study Design and Setting
The Xanthin study is a multi-centre, one-year double
blind randomized placebo controlled trial in subjects
with a renal transplant. The study is being conducted at
the Launceston General Hospital and Burnie Satellite
Renal Units in Northern Tasmania, which service a popu-
lation of approximately 250,000.
Ethical Considerations
The Tasmanian Statewide Scientific and Ethics Commit-
tees approved the Xanthin Trial. The Ethics Committees
will be provided with annual reports of the trial progress
and will promptly receive all adverse event reports.
Identification of Eligible Patients
The principal investigators and the clinical trial coordina-
tors will screen the medical records of patients prior to
their attendance at the renal clinics. Eligible patients will
have a copy of the patient information sheet placed in the
medical record. The principal investigator will then
explain the study during the clinical consultation. After
the explanation the subject will be provided with a patient
information sheet and informed consent form. The sub-
ject will then be asked to take this away with them and
arrangements will be made to follow up via a telephone
call. If the subject agrees to participate, they will sign the
consent form with an independent person signing as a
witness.
Eligibility
Inclusion criteria are; age > 18 and < 85 years having
undergone renal transplantation. Subjects will be
excluded if they are already taking antioxidant supple-
mentation, unable to take glyceryl trinitrate or are partici-
pating in, or propose to participate in, another clinical
drug study within 30 days prior to study entry.
Randomization
The clinical trial pharmacist at the Launceston General
Hospital or Royal Brisbane and Women's, who is inde-
pendent of the study team, will perform the randomiza-
tion. Subjects will also be stratified according to four
groups according to the type of immunosuppression used
for the renal transplant. The four groups will be those tak-
ing 1) cyclosporine, 2) tacrolimus, 3) sirolimus and 4)
prednisolone together with either azathioprine, myco-
phenolate mofetil or mycophenolate sodium. Computer
generated random numbers will be placed in blocks of ten
by the clinical trial pharmacist and related to a series of
drug code numbers. Each drug code assignment block will
refer to one of the stratification groups. Data recorded will
include the drug code number, which becomes the sub-
jects Xanthin trial identification number, the patient hos-
pital record number, the date of allocation, and the type
of immunosuppressant used. The sheet containing the
blocks of drug code numbers are given to the clinical trial
coordinator who thus is blinded to the allocation per-
formed by the pharmacist. Once the immunosuppressant
type is confirmed by the principal investigator the clinical
trial pharmacist selects the next available drug code
number from the relevant stratification block according to
the type of immunosuppressant. This enables the pharma-
cist at the patient's location to dispense from the appro-
priate randomization group. The subject receives a specific
purpose numbered Xanthin trial plastic container with
tablets enclosed, which are indistinguishable as to
whether they contain astaxanthin or placebo. The rand-
omization code is kept sealed in an opaque envelope in
the Launceston General Hospital and an identical copy is
kept at an off-site location of one of the associate investi-
gators for the duration of the study.
Study Medication and Dosing
Cyanotech Corporation provided the astaxanthin (BioAs-
tin) and identical placebo, which were shipped in con-
tainers from Hawaii. The astaxanthin is derived from
haematococcus pluvialis (microalge). Tablets will be
checked to ensure they will not exceed their expiry date at
any stage of their prescription to subjects. They will then
be placed in number coded containers so it is not possible
to distinguish, other than with the code, which container
has placebo or astaxanthin. Each group will take three tab-
lets (at one time point) per day. The active treatment is 12
mg of astaxanthin per day (3 × 4 mg tablets).BMC Nephrology 2008, 9:17 http://www.biomedcentral.com/1471-2369/9/17
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Primary Objectives and Primary Outcome Measures
The primary objectives are to assess the effects of astaxan-
thin on arterial stiffness, oxidative stress and inflamma-
tion. The primary outcome measures will be outlined
below. The hypotheses are that astaxanthin will signifi-
cantly improve the rates of change in these measures com-
pared with controls.
Arterial stiffness
Carotid to femoral PWV will be derived by electrocardiog-
raphy-gated sequential applanation tonometry (SPT-301
Mikro-Tip, Millar Instruments, Houston, Texas) using the
foot-to-foot method (SphymoCor™ 7.01 AtCor, Sydney,
Australia) [38]. Testing is performed in a temperature-
controlled room and after 5–10 minutes rest with the sub-
ject in the supine position prior to the first measure. Two
measures will be averaged for the estimation of aortic
PWV.
Oxidative stress and inflammation
The primary outcome measure for oxidative stress will
plasma isoprostanes measured using gas chromatography
mass spectrometry [39] and for inflammation, pentraxin
3 using an ELISA assay [40].
Secondary Objectives and Secondary Outcome Measures
Secondary objectives of the Xanthin trial are to assess the
effects of astaxanthin on vascular function and additional
measures of arterial stiffness, left ventricular afterload,
oxidative stress and inflammation.
Vascular function
Brachial artery reactivity (BAR) will be measured to assess
vascular function. A 12 MHz linear array transducer and
ultrasound scanner (Vivid i, GE Healthcare, USA) will be
used to record the dilator response of the brachial artery
to increased blood flow generated during reactive hyper-
aemia of the downstream forearm. The measures are per-
formed on the non-fistula arm; if one is still present. A
blood pressure cuff is placed on the upper forearm. The
brachial artery will be scanned in the longitudinal plane,
acquiring a baseline image about 5 cm above the antecu-
bital fossa. The transducer is left in this scanning position.
The cuff is then inflated to 220 mmHg for 4 minutes. Fol-
lowing cuff deflation, images will be acquired at 5 and 10
seconds then at 10-second intervals up to 120 seconds.
Following a 15-minute rest, this process is then repeated.
This allows the artery to return to baseline state. After
another 15 minutes an additional baseline image is
acquired and then 300 g of sublingual GTN will be
administered. After 3 minutes images of the brachial
artery are obtained as described above. All images are
stored for later offline analysis. The truest diameter will
evidenced by the "double line sign", i.e. crisp intima-
media and media-adventitia boundaries on the near and
far walls [41]. For all measures, the average of three diam-
eter measurements made along the artery, from the trail-
ing edge of intima-media to the leading edge of the
media-adventitia, as described by Aeschlimann et al [41],
will be used. BAR will be expressed as maximal dilatation
(mm), as a percentage change from baseline. The area
under the diameter/time curve (AUC) will also be used to
determine temporal changes using analytical imaging
software (Imaging Research, St. Catherine's, Canada) and
confirming with trapezoidal integration in Microsoft
Excel (Seattle, WA, USA) as we have done previously [42].
These will then be compared with the dilatation response
caused by the administration of sublingual glyceryl trini-
trate (GTN). This gives a ratio of endothelial dependant
and independent vascular function.
Arterial Stiffness and Left Ventricular Afterload
Carotid artery intimal medial thickness (CMIT) and aug-
mentation index (AIx) will be measured to further assess
arterial stiffness. Central pulse pressure will be used to
determine left ventricular afterload.
CIMT refers to the combined thickness of the intimal and
medial layers of the carotid arterial wall [43]. This corre-
sponds to the inner and outer echogenic lines seen on the
B-mode ultrasound image [44]. The CMIT will be assessed
using a 12 MHz linear array transducer and ultrasound
scanner (Vivid i, GE Healthcare, USA). Images will be
acquired from the anterior, posterior and lateral planes of
the right common carotid artery. The thickness will be
measured one to two centimetres proximal to the bifurca-
tion and during cardiac diastole from the far wall only as
there are technical and acoustic difficulties encountered
when measuring the near wall thickness [44]. For the pur-
pose of the analysis, the average of these three recordings
will be used. CIMT assessment will be performed in the
plaque-free arterial wall (an atherosclerotic plaque being
defined as an echo-structure protruding into the vascular
lumen and a thickness greater by at least 50% than neigh-
bouring sites [45].
Pulse wave analysis (PWA) will be used to derive a central
(ascending aortic) pressure waveform via applanation
tonometry at the radial artery [38] to determine central
pulse pressure and AIx as a composite measure of arterial
stiffness. This method involves uses a generalised transfer
function to transform the radial pressure waveform. The
central waveform will be calibrated by the average of two
measures of brachial blood pressure using a semi-auto-
mated device (UA-767, A&D).
Oxidative Stress and Inflammation
Additional secondary outcome measures for oxidative
stress and antioxidant status will include plasma protein
carbonyls, total antioxidant capacity, antioxidant enzymeBMC Nephrology 2008, 9:17 http://www.biomedcentral.com/1471-2369/9/17
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activities, and for inflammation, C reactive protein and a
cytokine panel consisting of IL-6, IL-8, IL-10 and TNF-
alpha.
Additional data to be collected will include self-reported
health (SF-36 questionnaire), physical activity levels
(items from the Active Australia questionnaire) nutri-
tional status (four-day diet diary), cardiovascular events,
mortality, hospital admissions, supplement safety and
tolerability. Based on our previous finding where antioxi-
dant supplementation with vitamin E resulted in a reduc-
tion in cyclosporine levels [37], patients will have a blood
sample taken one week after starting therapy to measure
immunosuppressant levels to assess whether any adverse
changes occur.
Visit One (baseline data)
The Xanthin study flow is summarized in Figure 1 and the
study evaluations are outlined in Table 2. After obtaining
informed consent patients will be contacted by telephone
by the trial coordinator at which a date and time is agreed
for subject to attend an appointment for baseline trial
measures. A letter of confirmation of this appointment
and a Xanthin Trial pathology request form will be
posted. Patients will be asked to attend the pathology lab-
oratory at least seven days before their first trial visit to
have a fasting blood sample collected. At the first trial
visit, additional data will be obtained from the medical
records (medical history, medications) and measures of
height, weight and blood pressure will be recorded. PWV,
PWA, CIMT and BAR measures will then be made. At the
completion of baseline data acquisition, the trial coordi-
nator explains and asks the subject to take home two
questionnaires (SF 36 and items from Active Australia)
and a four-day diet diary for completion. The subject is
supplied with a self-addressed express post envelope. Sub-
jects are asked to complete and post these tasks within the
following two weeks. Subjects are informed that visit two
will be approximately six months after visit one. At the
completion of visit one, the clinical trial coordinator will
provide patients with a three months supply of trial med-
ication as described in the section on randomization. Sub-
jects will be instructed to take three tablets each day
preferably with food. The same instructions are provided
on the medication container. Finally, participants are pro-
vided with a pathology request form for collection of
immunosuppressant levels post one-week initial con-
sumption of trial medication (to assess if there is any
change to the plasma immunosuppressive levels). Data
obtained at the scheduled study visits and are transcribed
onto case record forms for entry into a specifically
designed Xanthin trial database. Subjects are contacted by
telephone ten weeks after visit one, to ascertain their
progress with trial medication adherence. The next three
months of trial medications will be supplied to them by
post. Subjects are then reminded that they will be con-
tacted by telephone in two months time to confirm an
appointment date and time for visit two.
Visits two and three
These visits occur at six months and one year after base-
line. An envelope containing a letter confirming appoint-
ment, pathology request forms, four-day diet diary, SF 36
and physical activity surveys will be mailed to patients.
They will be asked to complete surveys and diet diary and
to attend the pathology laboratory seven days prior to vis-
its. Participants will also required to return empty tablet
containers and containers with remaining tablets and
issued with a further three-month supply of trial medica-
tion. At these visits, data acquisition from measures and
tests described above will be performed again.
Adherence to Study Medication
Sufficient medication is included in the containers to last
for six months. However, as a crosscheck of the subjects
Flow chart of Xanthin trial Figure 1
Flow chart of Xanthin trial.
Screen renal transplant 
patients
Age > 18yrs < 85 yrs
Excluded:
– taking antioxidant supplements
– unable to take GTN
– in another drug trial within 30 days
Randomisation
Stratiﬁcation
Astaxanthin 12 mg Placebo
Trial visits
– Baseline
–  6 months
– 12 months
Trial visits
– Baseline
–  6 months
– 12 monthsBMC Nephrology 2008, 9:17 http://www.biomedcentral.com/1471-2369/9/17
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adherence to drug therapy, each container has 300 tablets
placed in it for each trial visit and the subjects are not
informed that the containers have additional tablets. At
each trial visit the subject is required to return the con-
tainer. Two separate tablet counts are then conducted one
by the trial coordinator and the trial pharmacist. This ena-
bles a check on adherence to therapy by calculating the
difference between 300 and the days of therapy and com-
paring this with number of tablets left in the container.
Withdrawal from Study
Subjects will be withdrawn from the study at their request,
without prejudice, as documented and explained at the
time of consenting. Patients who withdraw will be asked
to consent to follow-up testing for the remainder of the
trial to enable an intention to treat data analysis.
Power calculation
Resource limitations will allow us to recruit 66 patients
within a two-year period. Data from other studies indi-
cates that Pentraxin 3 has the highest variability of the
three outcome measures (mean ± SD; isoprostanes = 54.1
± 7.0 [46], PWV = 11.4 ± 2.4 [47], pentraxin 3 = 0.75 ± 0.3
[48]). We assume that a decrease of 10% in pentraxin 3
would be clinically significant. Therefore, with alpha =
0.05, we will have about a 17% power to detect this 10%
change in pentraxin 3 and a 52% power to detect a 20%
change. This also allows for a 20% withdrawal rate. We
recognize that the power of the study is small, but believe
that the study will form the basis for progression to a
larger study.
Statistical analysis
All baseline continuous variables between groups will be
compared using general linear modelling, whilst categori-
cal variables will be compared using exact logistic regres-
sion. The rates of change will be estimated for each patient
separately by linear regression. General linear modelling,
will be used to compare the mean rate of change in pri-
mary outcome measures between groups, unadjusted and
adjusted for actual and potential confounding variables.
Mean differences, 95% confidence intervals and P-values
will be corrected for repeated measures, and P-values cor-
rected for multiple comparisons by the Holm method. All
analyses will be performed using Stata/IC 10.1 for Win-
dows (StataCorp LP, College Station, Tx).
Discussion
The objective of the Xanthin trial is to assess whether the
antioxidant astaxanthin can affect arterial stiffness, oxida-
tive stress and inflammation in renal transplant patients.
Data from this trial may lead to a larger scale intervention
study assessing major cardiovascular endpoints.
Although, previous studies using antioxidants have not
generally resulted in cardiovascular benefits [19,20], we
predict that because of its greater potency, astaxanthin will
provide vascular benefits and reduce measures of oxida-
tive stress and inflammation.
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Table 2: Outcome measures at baseline, 6 and 12 months
Primary Outcome Measures
Arterial stiffness – aortic pulse wave velocity (PWV)
Oxidative stress – plasma isoprostanes
Inflammation – plasma pentraxin 3
Secondary Outcome Measures
Arterial stiffness – augmentation index (AIx)
Arterial stiffness – carotid artery intimal medial thickness (CMIT)
Left ventricular overload – central pulse pressure
Vascular function – brachial artery reactivity (BAR)
Oxidative stress – plasma protein carbonyls
Antioxidant status – plasma total antioxidant capacity,
- plasma antioxidant enzyme activities
- plasma antioxidant enzyme activities
Inflammation – C reactive protein, IL-6, IL-8, IL-10 and TNF-alpha
Additional blood measures – full blood profile, electrolytes, liver function
- lipid profile
- plasma immunosuppressant levels
- eGFR
Adverse events
Concomitant therapy
Self reported health – SF 36
Physical Activity – items from the Active Australia questionnaire
Nutrition – four day diet diaryBMC Nephrology 2008, 9:17 http://www.biomedcentral.com/1471-2369/9/17
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